News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Oct 02, 2013
- New data reinforces the efficacy and safety profile of Sativex® in Multiple Sclerosis Spasticity-
Sep 23, 2013
London, UK; 23 September 2013: GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced today that agreement for a revised mutually-acceptable reimbursement price for Sativex® has been reached between Almiral
Sep 18, 2013
London, UK; 18 September 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epil
Jul 22, 2013
London, UK, 22 July 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutic
Jul 15, 2013
London, UK, 15 July 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its propri
Jul 08, 2013
London, UK, 08 July 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutic
Jun 03, 2013
- GW Pharmaceuticals plc Reports 2013 Second Quarter Financial Results Conference Call Today at 8:00 a.m. ET, 1:00 p.m. BST -

Pages